These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33281191)

  • 1. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
    Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
    Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
    Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
    Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
    Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
    Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.
    Stevenson MJ; Phanor SK; Patel U; Gisselbrecht SS; Bulyk ML; O'Brien LL
    Dis Model Mech; 2023 Nov; 16(11):. PubMed ID: 37815464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
    Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
    Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition.
    Li CM; Guo M; Borczuk A; Powell CA; Wei M; Thaker HM; Friedman R; Klein U; Tycko B
    Am J Pathol; 2002 Jun; 160(6):2181-90. PubMed ID: 12057921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
    Sehic D; Karlsson J; Sandstedt B; Gisselsson D
    Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.
    Torrezan GT; Ferreira EN; Nakahata AM; Barros BD; Castro MT; Correa BR; Krepischi AC; Olivieri EH; Cunha IW; Tabori U; Grundy PE; Costa CM; de Camargo B; Galante PA; Carraro DM
    Nat Commun; 2014 Jun; 5():4039. PubMed ID: 24909261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers.
    Imam JS; Buddavarapu K; Lee-Chang JS; Ganapathy S; Camosy C; Chen Y; Rao MK
    Oncogene; 2010 Sep; 29(35):4971-9. PubMed ID: 20603620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss or oncogenic mutation of DROSHA impairs kidney development and function, but is not sufficient for Wilms tumor formation.
    Kruber P; Angay O; Winkler A; Bösl MR; Kneitz S; Heinze KG; Gessler M
    Int J Cancer; 2019 Mar; 144(6):1391-1400. PubMed ID: 30367465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor.
    Sehic D; Ciornei CD; Gisselsson D
    Am J Clin Pathol; 2014 Jun; 141(6):828-33. PubMed ID: 24838327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widening the spectrum of players affected by genetic changes in Wilms tumor relapse.
    Ciceri S; Bertolotti A; Serra A; Gattuso G; Boschetti L; Capasso M; Cecchi C; Sorrentino S; Quarello P; Ciniselli CM; Verderio P; De Cecco L; Manenti G; Diomedi Camassei F; Collini P; Spreafico F; Perotti D
    iScience; 2024 Sep; 27(9):110684. PubMed ID: 39262773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of promoter methylation and expression of SIX2 as a diagnostic and prognostic biomarker in Wilms' tumor.
    Song D; Yue L; Wu G; Ma S; Guo L; Yang H; Liu Q; Zhang D; Xia Z; Wang L; Zhang J; Zhao W; Guo F; Wang J
    Tumour Biol; 2015 Sep; 36(10):7591-8. PubMed ID: 25921281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Analyses Reveal the Relationship Between SIX1/EYA1 Mutations and Conotruncal Heart Defects.
    Li B; Xu L; Hong N; Chen S; Xu R
    Pediatr Cardiol; 2018 Jan; 39(1):176-182. PubMed ID: 29043394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of
    Ciceri S; Gamba B; Corbetta P; Mondini P; Terenziani M; Catania S; Nantron M; Bianchi M; D'Angelo P; Torri F; Macciardi F; Collini P; Di Martino M; Melchionda F; Di Cataldo A; Spreafico F; Radice P; Perotti D;
    Oncotarget; 2018 Sep; 9(75):34079-34089. PubMed ID: 30344923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia.
    Grønskov K; Olsen JH; Sand A; Pedersen W; Carlsen N; Bak Jylling AM; Lyngbye T; Brøndum-Nielsen K; Rosenberg T
    Hum Genet; 2001 Jul; 109(1):11-8. PubMed ID: 11479730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-188 is downregulated in oral squamous cell carcinoma and inhibits proliferation and invasion by targeting SIX1.
    Wang L; Liu H
    Tumour Biol; 2016 Mar; 37(3):4105-13. PubMed ID: 26490981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
    Smith AL; Iwanaga R; Drasin DJ; Micalizzi DS; Vartuli RL; Tan AC; Ford HL
    Oncogene; 2012 Dec; 31(50):5162-71. PubMed ID: 22286770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.